This video shows a solid tumor sample derived from a pancreatic xenograft model that was used to test the efficacy of CAR T cell therapies. For visualization and analysis, the following channels were used: tumor surface (autofluorescence), tumor vasculature (rhodamine lectin), and CAR T cells (CD3-Vio667). The sample was cleared with the MACS® Clearing Kit and imaged with the UltraMicroscope Blaze™ in MACS Imaging Solution. For more information, please refer to Pfeifer et al. (2022): A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level." Theranostics 12.11: 4834-4850.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
